John W. Kozarich - 17 Jan 2025 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: John W. Kozarich
Issuer symbol
LGND
Transactions as of
17 Jan 2025
Net transactions value
+$125,834
Form type
4
Filing time
02 Jun 2025, 20:05:50 UTC
Previous filing
18 Jun 2024
Next filing
10 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KOZARICH JOHN W Director 555 HERITAGE DRIVE, SUITE 200, JUPITER By: /s/ Andrew Reardon, Attorney-in-Fact For: John W. Kozarich 02 Jun 2025 0001223000

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $125,834 +2,406 +5.5% $52.30 46,181 17 Jan 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -2,406 -100% $0.000000 0 17 Jan 2025 Common Stock 2,406 $52.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Option was previously reported as a Grant of 2,754 shares, which vested in full on April 24, 2016, at an exercise price of $89.7500 per share.